<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="23877">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795949</url>
  </required_header>
  <id_info>
    <org_study_id>SIMPLFY</org_study_id>
    <nct_id>NCT02795949</nct_id>
  </id_info>
  <brief_title>Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae</brief_title>
  <acronym>SIMPLIFY</acronym>
  <official_title>Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spanish Network for Research in Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Pública Andaluza para la gestión de la Investigación en Sevilla</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The continuous increase in the bacterial resistance rate and the slow arrival of new
      therapeutic options have turned into an antibiotic crisis. One of the strategies proposed by
      stewardship programs to try to change this situation described worldwide is the use of
      antibiotics with the lowest possible antimicrobial spectrum.

      Enterobacteriaceae bacteremia is a good example of how this strategy would be applied. The
      empirical treatment of nosocomial bacteremia by Enterobacteriaceae comprises in several
      cases one or two antibiotics with antipseudomonal activity, being much less common than
      desirable a subsequent change to narrower spectrum antibiotics based on susceptibility data
      (&quot;de escalation&quot;). This is because the safety of de escalation is based only on expert
      advice and some observational studies, so their efficacy and safety is questioned by many
      clinicians and therefore its use is lower than desired. In fact, a recent systematic review
      of the Cochrane Library concluded that randomized studies to support this practice are
      needed. Investigators propose a &quot;real clinical practice-based&quot; randomized trial to compare
      the efficacy and safety of continuing with an antipseudomonal agents vs. de-escalation
      according to a pre-specified rule, in patients with bacteraemia due to Enterobacteriaceae.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure at day 3-5 after treatment.</measure>
    <time_frame>Day 3-5 after end of treatment</time_frame>
    <description>Clinical cure: complete resolution of infection symptoms (bacteremia) present at the day on which the assessment is done and patient is alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early clinical and microbiological response.</measure>
    <time_frame>After 5 days of treatment</time_frame>
    <description>The infection was completely resolved after 5 days of treatment (patients without infection symptoms and a negative blood culture).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late clinical and microbiological response.</measure>
    <time_frame>Day 60</time_frame>
    <description>The infection was completely resolved at day 60 (patients without infection symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>At 7,14 and 30 days</time_frame>
    <description>Death for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>At 7,14 and 30 days</time_frame>
    <description>Defined as the from admission to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrences (relapse or reinfection) rate</measure>
    <time_frame>Day 60 after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of antibiotic treatment</measure>
    <time_frame>60 days</time_frame>
    <description>Gathering any related adverse event from the informed consent form signature up to 60 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of the study treatment on intestinal microbiota</measure>
    <time_frame>Screening, Day 7-14, Day 12-21, Day 30</time_frame>
    <description>Effect of study treatment on colonization of the intestinal tract with multi drug resistant gram negative bacilli</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">344</enrollment>
  <condition>Enterobacteriaceae Infections</condition>
  <arm_group>
    <arm_group_label>Antipseudomonal beta-lactam antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ampicillin 2g IV/6h
Trimethoprim/sulfamethoxazole 160/800 mg IV/8 -12h
Cefuroxime 750-1000 mg IV/8h
Cefotaxime 1-2g IV/8h ó ceftriaxone 1 g/12-24h
Amoxicillin/clavulanate 1000/125 mg IV/8h
Ciprofloxacin 400 mg IV/12h
Ertapenem 1g/24h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>De-escalation(short-spectrum antibiotic)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Piperacillin/tazobactam 4/0.5 g IV/8h
Meropenem 1-2 g IV/8h
Imipenem 0.5 g IV/6h - 1g IV/6h
Aztreonam 1-2 g IV/8h
Ceftazidime 1-2 g IV/8h
Cefepime 2 g IV/8-12h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antipseudomonal beta-lactam antibiotic</intervention_name>
    <description>Pharmaceutical form: solution for infusion</description>
    <arm_group_label>Antipseudomonal beta-lactam antibiotic</arm_group_label>
    <other_name>Ampicillin</other_name>
    <other_name>Trimethoprim/sulfamethoxazole</other_name>
    <other_name>Cefuroxime</other_name>
    <other_name>Amoxicillin/clavulanate</other_name>
    <other_name>Ciprofloxacin</other_name>
    <other_name>Ertapenem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>De-escalation(short-spectrum antibiotic)</intervention_name>
    <description>Pharmaceutical form: solution for infusion</description>
    <arm_group_label>De-escalation(short-spectrum antibiotic)</arm_group_label>
    <other_name>Piperacillin/tazobactam</other_name>
    <other_name>Meropenem</other_name>
    <other_name>Imipenem</other_name>
    <other_name>Aztreonam</other_name>
    <other_name>Ceftazidime</other_name>
    <other_name>Cefepime</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. ≥18 years old hospitalized patients with bacteremia from any source with isolation of
             an enterobacteria in blood cultures.

          2. Active empiric treatment with antipseudomonal betalactamic at 48 hours from the
             symptoms of sepsis and the blood culture.

          3. Microorganism susceptible at least one treatment from the experimental arm.

          4. Patients with intravenous treatment at least 5 days.

          5. Patients to sign the informed consent form.

        Exclusion Criteria:

          1. Palliative care or life expectance &lt; 90 days.

          2. Pregnancy or lactation period.

          3. To isolate the Extended-spectrum β-lactamases producing Enterobacteriaceae

          4. Late randomization &gt;48 hours after the enterobacteriaceae blood culture´s
             identification

          5. Severe neutropenic (&lt; 500 céls/mm3) at the randomization.

          6. Treatment of infection &gt; 28 days (endocarditis and osteomyelitis) or meningitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis Eduardo Lopez Cortes, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitary Hospital Virgen Macarena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clara Rosso Fernández, MD, PhD</last_name>
    <phone>0034 955016414</phone>
    <email>claram.rosso.sspa@juntadeandalucia.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lucía Lavín Alconero, BS, PhD</last_name>
    <phone>0034 955013414</phone>
    <email>lucia.lavin.exts@juntadeandalucia.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Mutua de Tarrasa</name>
      <address>
        <city>Tarrasa</city>
        <state>Barcelona</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucía Gómez García, MD</last_name>
      <email>lgomez@mutuaterrassa.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jerez de la Frontera Hospital</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11138</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador Pérez Cortes, MD</last_name>
      <email>salvador.perez.cortes.sspa@juntadeandalucia.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Donostia</name>
      <address>
        <city>San Sebastian</city>
        <state>Gipúzcoa</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maialen Ibarguren Pinilla, MD</last_name>
      <email>MAIALEN.IBARGURENPINILLA@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Teresa Pérez Rodríguez, MD, PhD</last_name>
      <email>maria.teresa.perez.rodriguez2@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Juan de Dios del Aljarafe Hospital</name>
      <address>
        <city>Bormujos</city>
        <state>Sevilla</state>
        <zip>41930</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocío Fernández Ojeda, MD, PhD</last_name>
      <email>MariaRocio.Fernandez@sjd.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03012</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esperanza Merino de Lucas, MD</last_name>
      <email>merino_luc@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Puerta del Mar</name>
      <address>
        <city>Cádiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisca Guerrero Sánchez, MD, PhD</last_name>
      <email>fcam.gs@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Puerto Real Hospital</name>
      <address>
        <city>Cádiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Jimenez, MD</last_name>
      <email>patriciajaguilar@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Salas Aparicio, MD</last_name>
      <email>asalasapa@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belen Loeches Yagüe, MD, Ms.C</last_name>
      <email>bloeches@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Son Espases Hospital</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Clinic of Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mª Carmen Fariñas Álvarez, MD, PhD</last_name>
      <email>mcfarinas@humv.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Juan de Dios de Sevilla Hospital</name>
      <address>
        <city>Sevilla</city>
        <zip>41005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen Macarena</name>
      <address>
        <city>Seville</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Eduardo López Cortés, MD, PhD</last_name>
      <email>luiselopezcortes@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Zaragoza</name>
      <address>
        <city>Zaragoza</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.reipi.org/</url>
    <description>Spanish Network for Research in Infectious Diseases (Red Española de Investigación en Patología Infecciosa)</description>
  </link>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 9, 2016</lastchanged_date>
  <firstreceived_date>April 1, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enterobacteriaceae</keyword>
  <keyword>Bacteremia</keyword>
  <keyword>Escalation</keyword>
  <keyword>Bacterial resistance</keyword>
  <keyword>Bloodstream infection</keyword>
  <keyword>Recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Enterobacteriaceae Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Ertapenem</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>beta-Lactams</mesh_term>
    <mesh_term>Lactams</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Cefuroxime</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Aztreonam</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
